Opioid analgesics /certified fixed orthodontic courses by Indian dental academy

1,342 views

Published on



The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.

Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
0091-9248678078

Published in: Education
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
1,342
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
3
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Opioid analgesics /certified fixed orthodontic courses by Indian dental academy

  1. 1. OPIOID ANALGESICS INDIAN DENTAL ACADEMY Leader in continuing dental education www.indiandentalacademy.com www.indiandentalacademy.com
  2. 2. History of Opioids • Opium is extracted from poppy seeds (Paper somniforum) • Used for thousands of years to produce: – Euphoria – Analgesia – Sedation – Relief from diarrhea – Cough suppression www.indiandentalacademy.com
  3. 3. History cont’d • Used medicinally and recreationally from early Greek and Roman times • Opium and laudanum (opium combined with alcohol) were used to treat almost all known diseases • Morphine was isolated from opium in the early 1800’s and since then has been the most effective treatment for severe pain www.indiandentalacademy.com
  4. 4. History and Background • Invention of the hypodermic needle in 1856 produced drug abusers who self administered opioids by injection • Controlling the widespread use of opioids has been unsuccessful because of the euphoria, tolerance and physiological dependence that opioids produce www.indiandentalacademy.com
  5. 5. Terminology • “opium” is a Greek word meaning “juice,” or the exudate from the poppy • “opiate” is a drug extracted from the exudate of the poppy • “opioid” is a natural or synthetic drug that binds to opioid receptors producing agonist effects www.indiandentalacademy.com
  6. 6. Natural opioids occur in 2 places: • 1) In the juice of the opium poppy (morphine and codeine) • 2) As endogenous endorphins • All other opioids are prepared from either morphine (semisynthetic opioids such as heroin) or they are synthesized from precursor compounds (synthetic opioids such as fentanyl) www.indiandentalacademy.com
  7. 7. Pharmacological Effects • Sedation and anxiolysis – – – – Drowsiness and lethargy Apathy Cognitive impairment Sense of tranquility • Depression of respiration – Main cause of death from opioid overdose – Combination of opioids and alcohol is especially dangerous • Cough suppression – Opioids suppress the “cough center” in the brain • Pupillary constriction – pupillary constriction in the presence of analgesics is characteristic of opioid use www.indiandentalacademy.com
  8. 8. Pharmacological effects cont’d. • Nausea and vomiting – Stimulation of receptors in an area of the medulla called the chemoreceptor trigger zone causes nausea and vomiting – Unpleasant side effect, but not life threatening • Gastrointestinal symptoms – Opioids relieve diarrhea as a result of their direct actions on the intestines • Other effects – Opioids can release histamines causing itching or more severe allergic reactions including bronchoconstriction – Opioids can affect white blood cell function and immune function www.indiandentalacademy.com
  9. 9. Mechanism of action • Activation of peripheral nociceptive fibers causes release of substance P and other painsignaling neurotransmitters from nerve terminals in the dorsal horn of the spinal cord • Release of pain-signaling neurotransmitters is regulated by endogenous endorphins or by exogenous opioid agonists by acting presynaptically to inhibit substance P release, causing analgesia www.indiandentalacademy.com
  10. 10. Primary Effect of Opioid Receptor Activation • Reduction or inhibition of neurotransmission, due largely to opioid-induced presynaptic inhibition of neurotransmitter release • Involves changes in transmembrane ion conductance – Increase potassium conductance (hyperpolarization) – Inactivation of calcium channels www.indiandentalacademy.com
  11. 11. Three Opioid Receptors • Mu • Kappa • Delta www.indiandentalacademy.com
  12. 12. Delta Receptor • It is unclear what delta’s responsible for. • Delta agonists show poor analgesia and little addictive potential • May regulate mu receptor activity www.indiandentalacademy.com
  13. 13. Mu-Receptor: Two Types • Mu-1 • Mu-2 – Located outside spinal cord – Responsible for central interpretation of pain – Located throughout CNS – Responsible for respiratory depression, spinal analgesia, physical dependence, and euphoria www.indiandentalacademy.com
  14. 14. Kappa Receptor • Only modest analgesia • Little or no respiratory depression • Little or no dependence • Dysphoric effects www.indiandentalacademy.com
  15. 15. Mu and Kappa Receptor Activation Response Mu-1 Mu-2 Analgesia Respiratory Depression Euphoria Dysphoria Decrease GI motility Physical Dependence www.indiandentalacademy.com Kappa
  16. 16. Mu and Kappa Receptors DRUGS MU KAPPA Agonist Agonist AgonistAntagonist Antagonist Agonist Pure Antagonists Antagonist Antagonist Pure Agonists www.indiandentalacademy.com
  17. 17. Terminology • Pure Agonist: has affinity for binding plus efficacy • Pure Antagonist: has affinity for binding but no efficacy; blocks action of endogenous and exogenous ligands • Mixed Agonist-Antagonist: produces an agonist effect at one receptor and an antagonist effect at another • Partial Agonist: has affinity for binding but low efficacy www.indiandentalacademy.com
  18. 18. AGONISTS *Morphine *Heroin *Hydromorphone *Fentanyl www.indiandentalacademy.com *Codeine
  19. 19. General Pharmacokinetics • LATENCY TO ONSET • *oral (15-30 minutes) • *intranasal (2-3 minutes) • *intravenous (15 – 30 seconds) • *pulmonary-inhalation (6-12 seconds) • DURATION OF ACTION – anywhere between 4 and 72 hours depending on the substance in question. • Metabolism – hepatic via phase 1 and phase 2 biotransformations to form a diverse array of metabolites ( eg., morphine to morphine-6-glucuronide). www.indiandentalacademy.com
  20. 20. Morphine • • • • • • • • • • • • • PHARMACOKINETICS Routes of administration (preferred) *Oral latency to onset –(15 – 60 minutes ) * it is also sniffed, swallowed and injected. * duration of action – ( 3 – 6 hours) * First-pass metabolism results in poor availability from oral dosing. * 30% is plasma protein bound EFFECTS AND MEDICAL USES *symptomatic relief of moderate to severe pain *relief of certain types of labored breathing *suppression of severe cough (rarely) *suppression of severe diarrhea *AGONIST for mu, kappa, and delta receptors. www.indiandentalacademy.com
  21. 21. Hydromorphone • • • • • • • • • • • • PHARMACOKINETICS *Routes of administration (Preferred) *Oral *latency to onset (15 – 30 minutes) *Intravenous *Duration of Action (3-4 hours) *Peak effect (30-60 minutes) PROPERTIES AND EFFECTS * potent analgesic like morphine but is 7-10 times as potent in this capacity. *used fequently in surgical settings for moderate to severe pain. (cancer, bone trauma, burns, renal colic.) www.indiandentalacademy.com
  22. 22. Fentanyl • • Pharmacokinetics Routes of Administration * Oral, and transdermal (possibly intravenous) *Highly lipophilic *latency to onset (7-15 minutes oral; 12-17 hours transdermal *duration of action ( 1-2 hours oral; 72 transdermal) *80 – 85% plasma protein bound *90 % metabolized in the liver to inactive metabolites Other properties * 80 times the analgesic potency of morphine and 10 times the analgesic potency of hydromorphone. *high efficacy for mu 1 receptors. *most effective opiate analgesic www.indiandentalacademy.com
  23. 23. Antagonists • • Naloxone Naltrexone www.indiandentalacademy.com
  24. 24. Naltrexone • • • • • • • • • • • • • • PHARMACOKINETICS *latency to onset (oral tablet 15-30 min.) *duration of action 24-72 hours *peak effect (6-12 hours) STRUCTURAL DISTINCTION *Differs from naloxone insofar as the allyl group on the nitrogen atom is supplanted by a cyclopromethyl group. EFFECTS *Reverses the psychotomimetic effects of opiate agonists. * Reverses hypotension and cardiovascular instability secondary to endogeneous endorphins (potent vasodilators) *inhibits Mu, Delta, and Kappa receptors. www.indiandentalacademy.com
  25. 25. Tolerance and Dependence www.indiandentalacademy.com
  26. 26. Tolerance • Tolerance is a diminished responsiveness to the drug’s action that is seen with many compounds • Tolerance can be demonstrated by a decreased effect from a constant dose of drug or by an increase in the minimum drug dose required to produce a given level of effect • Physiological tolerance involves changes in the binding of a drug to receptors or changes in receptor transductional processes related to the drug of action • This type of tolerance occurs in opioids www.indiandentalacademy.com
  27. 27. Tolerance continued • Molecular basis of tolerance involves glutaminergic mechanisms (glutamate-excitatory amino acid neurotransmitter) • 1997, Gies and colleagues stated that activation of glutamate NMDA receptors correlates with resistance to opioids and the development of tolerance • Mu-receptor mRNA levels are regulated by activation of these receptors • NMDA receptor blocker ketamine prevented the development of this late-onset and long-lasting enhancement in pain sensitivity after the initial analgesia effect dissipated www.indiandentalacademy.com
  28. 28. Tolerance continued • Thus, glutaminergic NMDA receptors MAY regulate mureceptor mRNA, accounting for the development of tolerance to the continuous presence of opioid • Cross-tolerance is the condition where tolerance for one drug produces tolerance for another drug – person who is tolerant to morphine will also be tolerant to the analgesic effect of fentanyl, heroin, and other opioids • * note that a subject may be physically dependent on heroin can also be administered another opioid such as methadone to prevent withdrawl reactions • Methadone has advantages of being more orally effective and of lasting longer than morphine or heroin www.indiandentalacademy.com
  29. 29. Tolerance continued • Methadone maintenance programs allow heroin users the opportunity to maintain a certain level of functioning without the withdrawl reactions • Although most opioid effects show tolerance, locomotor stimulation shows sensitization with repeated opioid administration • Toxic effects of opioids are primarily from their respiratory depressant action and this effect shows tolerance with repeated opioid use • Opioids might be considered “safer” in that a heroin addicts drug dose would be fatal in a first-time heroin user www.indiandentalacademy.com
  30. 30. Dependence • Physiological dependence occurs when the drug is necessary for normal physiological functioning – this is demonstrated by the withdrawl reactions • Withdrawl reactions are usually the opposite of the physiological effects produced by the drug www.indiandentalacademy.com
  31. 31. Withdrawl Reactions Acute Action • • • • • • • • • • • • Withdrawl Sign • Pain and irritability Analgesia • Hyperventilation Respiratory Depression • Dysphoria and depression Euphoria • Restlessness and insomnia Relaxation and sleep • Fearfulness and hostility Tranquilization • Increased blood pressure Decreased blood pressure • Diarrhea Constipation • Pupillary dilation Pupillary constriction • Hyperthermia Hypothermia • Lacrimation, runny nose Drying of secretions • Spontaneous ejaculation Reduced sex drive • Chilliness and “gooseflesh” Flushed and warm skin www.indiandentalacademy.com
  32. 32. Dependence continued • Acute withdrawl can be easily precipitated in drug dependent individuals by injecting an opioid antagonist such as naloxone or naltrexone – rapid opioid detoxification or rapid anesthesia aided detoxification • The objective is to enable the patient to tolerate high doses of an opioid antagonist and undergo complete detox in a matter of hours while unconscious • After awakening, the person is maintained on orally administered naltrexone to reduce opioid craving www.indiandentalacademy.com
  33. 33. Chapter 10: Nonnarcotic, AntiInflammatory Analgesics Treatment for: mild to moderate pain, fever, inflammation, stroke/heart attack prevention, arthritis, *? prevention of Alzheimer’s Dementia www.indiandentalacademy.com
  34. 34. Aspirin and related NSAIDs • display a ceiling effect for analgesia (not as effective as opioids) • can be used in combination with opiate analgesics (summation effect) www.indiandentalacademy.com
  35. 35. History/Actions Bark of willow tree: Pain relief from chemical in bark, salicin (chemically related to aspirin) NSAID prototype: Acetylsalicylic acid (ASA) = aspirin Action of NSAIDs: through either selective or non-selective blocking of enzymes involved in the synthesis of prostaglandins NSAID= non-steroidal anti-inflammatory drug www.indiandentalacademy.com
  36. 36. PROSTAGLANDINS • Members of group of lipid-derived paracrines Paracrines: • chemicals secreted by a cell to act on cells in the immediate vicinity via process of diffusion • Can be released by all cells in the body www.indiandentalacademy.com
  37. 37. Cyclooxygenase • An enzyme involved in prostaglandin synthesis – cyclooxygenase-1 (COX-1): beneficial prostaglandins – cyclooxygenase-2 (COX-2): harmful prostaglandins www.indiandentalacademy.com
  38. 38. COX Enzyme:Prostaglandin Effects COX-1: beneficial COX-2: harmful Peripheral injury site Inflammation Brain Modulate pain perception Promote fever (hypothalamus) Stomach protect mucosa Platelets aggregation Kidney vasodilation www.indiandentalacademy.com
  39. 39. Effects of COX Inhibition by Most NSAIDS COX-1 COX-2 Reduce inflammation Gastric ulcers Bleeding Reduce pain Acute renal failure Reduce fever NSAIDs : anti-platelet—decreases ability of blood to clot www.indiandentalacademy.com
  40. 40. Pharmacokinetics: ASA Absorption: from stomach and intestine Distribution: readily, into most fluids/tissues Metabolism : primarily hepatic • ASA contraindicated for use in children with viral fever –can lead to Reye’s Syndrome • Fatal overdose is possible Similar pharmacokinetics for ibuprofen and related NSAIDs www.indiandentalacademy.com
  41. 41. Pharmacokinetic Variability of Non-Selective COX-Inhibitors Name Time to peak ½ life parent (hours) ½ life*active Aspirin 1-2 0.25-0.33 (*3-10 L-H) Naproxen Oxaprozin 2-4 3-5 12-15 42-50 *Sulindac (pro-drug) 2-4 7.8 (*16.4) Ketorolac (inj) 3.8-8.6 Ibuprofen .5-1 www.indiandentalacademy.com 1-2 1.8-2.5
  42. 42. Selective Cox-2 Inhibitors • Greater affinity for cyclooxygenase-2 • Decreased incidence of negative effects associated with non-selective COX-inhibitors Name Time to peak (hours) ½ life (hours) Celecoxib 3 11 Rofecoxib 2-3 17 www.indiandentalacademy.com
  43. 43. Acetaminophen N-Acetyl-P-Aminophenol (APAP) Classification: analgesic, antipyretic, misc. not an NSAID Mechanism: inhibits prostaglandin synthesis via CNS inhibition of COX (not peripheral)---doesn’t promote ulcers, bleeding or renal failure; peripherally blocks generation of pain impulses, inhibits hypothalamic heat-regulation center www.indiandentalacademy.com
  44. 44. APAP Liver Metabolism 1. Major pathway —Majority of drug is metabolized to produce a non-toxic metabolite 2. Minor pathway —Produces a highly reactive intermediate (acetylimidoquinone) that conjugates with glutathione and is inactivated. • At toxic APAP levels, minor pathway metabolism cannot keep up (liver’s supply of glutathione is limited), causing an increase in the reactive intermediate which leads to hepatic toxicity and necrosis www.indiandentalacademy.com
  45. 45. Pharmacokinetics: APAP Metabolism: major and minor pathways Half-life: 1-3 hours Time to peak concentration: 10-60 min Treatment for overdose: Acetylcysteine (Mucomyst) www.indiandentalacademy.com
  46. 46. See “New Approach…Pain” • http://www.drugabuse.gov/NIDA_Notes/NNVo www.indiandentalacademy.com
  47. 47. Thank you For more details please visit www.indiandentalacademy.com www.indiandentalacademy.com

×